Molnupiravir

  • Medicine Name- Lagevrio 
  • API- Molnupiravir
  • Packaging- Capsule
  • Strength- Capsules: 200 mg
Get an Enquiry

Description

Patients with COVID-19 are now being treated with Molnupiravir 200 Mg Capsule, which was originally developed for the treatment of influenza. It lessens the severity of the illness by interfering with SARS-CoV-2 replication.

Dosage and Side Effects

  • For five days, 800 mg (four 200 mg capsules) should be taken orally every twelve hours with or without food. 
  • Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.
  • Molnupiravir is not authorized for use for longer than 5 consecutive days because the safety and efficacy have not been established.  
  • If the patient misses a dose of Molnupiravir 200 mg Capsule within 10 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. 
  • The patient should not double the dose to make up for a missed dose. 

Most common adverse reactions  are diarrhea, nausea, and dizziness.

Warning and Precautions

  • It is not advised to use Molnupiravir 200 mg Capsule when expecting as it can cause embryo fetal toxicity.
  • Breastfeeding should be stopped for four days after starting molnupiravir capsule therapy as well as during the course of treatment.
  • With Molnupiravir Capsule, reports of hypersensitivity responses, including anaphylaxis, have been made. Stop taking Molnupiravir right away if you experience any symptoms of a clinically serious hypersensitivity response or anaphylaxis.
  • Due to potential effects on bone and cartilage formation, Molnupiravir Capsule is not permitted for use in patients under the age of 18.

FAQ's

Has molnupiravir been FDA approved?

On February 1, 2023, the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorizations (EUAs) for Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) and Lagevrio™ (molnupiravir), removing the requirement for positive SARS-CoV-2 test results prior to prescribing.

Who Cannot use Molnupiravir Capsule?

HIV or AIDS and have a weakened immune system; a condition affecting your immune system. a condition affecting the brain or nervous system, such as multiple sclerosis, muscular dystrophy, motor neurone disease, myasthenia gravis, Huntington’s disease, Parkinson’s disease or certain types of dementia.

Is molnupiravir safe for adults?

Adults aged 18 years and older can take molnupiravir Capsule.

Does molnupiravir cause kidney damage?

No adverse effects were observed in any patient. Renal function remained stable in the two CKD patients who were not on dialysis.

When is the best time to take molnupiravir Capsule?

The recommended Molnupiravir dosage in adult patients is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food.